New heart device aims to cut stroke risk without lifelong pills
NCT ID NCT07278869
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new device called the Append System in 15 adults with atrial fibrillation (a type of irregular heartbeat). The device is threaded through a blood vessel to close off a small pouch in the heart called the left atrial appendage, where clots often form. The goal is to see if the procedure is safe and can reduce stroke risk, potentially offering an alternative to long-term blood thinners.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Append System (a catheter-based device that closes the left atrial appendage by turning it inside out and tying it off)
- What this could lead to
- If this device works safely, it could offer a new way to lower stroke risk in people with atrial fibrillation who cannot take blood thinners long-term.
- What could go wrong
- This is a very early feasibility study with only 15 people, so results may not apply broadly. The procedure carries risks like stroke, bleeding, or heart sac inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Mar 2033
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or non-pregnant female aged ≥18 years 2. Documented non-valvular AF (paroxysmal, persistent, permanent or non-rheumatic valve-related AF) 3. The subject has a calculated CHA2DS2-VASc score of 2 or greater for males or 3 or greater for females. 4. The subject is eligible for the defined protocol medication regimen of anticoagulation and antiplatelet therapy following Append procedure. 5. The patient is deemed appropriate for LAA ligation by the screening committee and the investigator. 6. The patient has been informed of the nature of the study, agrees to its provisions \& follow-up evaluations, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC). General Exclusion Criteria: 1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure. 2. Atrial fibrillation that is defined by a single occurrence or that is considered to be reversible (e.g., due to thyroid disorders, acute alcohol intoxication, trauma, or recent major surgical procedures). 3. Patients with an indication for chronic oral anticoagulation other than AF (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve) 4. Clinically significant Severe heart failure (New York Heart Association functional class IV) 5. Prior cardiac surgery or surgery requiring sternotomy 6. Recent (within 3 months pre-procedure) stroke or transient ischemic attack. 7. Recent (within 3 months pre-procedure) myocardial infarction 8. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac interventional procedures (e.g., percutaneous coronary intervention, structural heart valve procedures, etc.) 9. Planned (within 60 days after the index procedure) cardiac surgical procedures or any surgeries which require sternotomy. 10. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) noncardiac procedures or surgical interventions. 11. History of symptomatic pericarditis (acute or chronic). 12. Patient has evidence of cardiac tumor 13. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation), or dialysis at the time of screening 14. Platelet count \<50,000 cells/mm3 or \>700,000 cells/mm3, or white blood cell count \<3,000 cells/mm3 or known Bleeding diathesis 15. Active infection with bacteremia 16. Patient has a known allergy, hypersensitivity or contraindication to aspirin, heparin, or that would preclude any P2Y12 inhibitor therapy, or the patient has contrast sensitivity that cannot be adequately pre-medicated 17. Current participation in another investigational drug or device study that would interfere with this study 18. Patient is unable to undergo general anesthesia 19. Patient has a condition which precludes adequate transesophageal echocardiographic (TEE) or computed tomographic (CT) assessment. 20. Known other medical illness or known history of substance abuse that may cause non-compliance with the specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 5 years. Cardiac Imaging Exclusion Criteria: 1. Intracardiac thrombus observed during screening 2. Left ventricular ejection fraction (LVEF) \<30% 3. Circumferential pericardial effusion \>5 mm or signs / symptoms of acute or chronic pericarditis, or evidence of tamponade physiology 4. Distance from inter-atrial septum fossa ovalis to LAA ostium is less than 40 mm 5. Any anatomy or prior intervention that would preclude a transseptal approach (including, but not limited to, prior IVC filter placement that cannot be crossed, prior ASD, or prior PFO closure device implantation that precludes transseptal puncture) 6. LAA structure that in the opinion of the screening committee / investigator precludes intervention
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non valvular atrial fibrillation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Arrhythmia Research Group
RECRUITINGJonesboro, Arkansas, 72401, United States
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tying off a heart pocket: a new way to prevent strokes without blood thinners?
- Can a common blood thinner shield your brain from dementia?
- Heart procedure showdown: which imaging method is safer?
- Researchers fine-tune blood thinner dosing for chinese heart patients
- Heart procedure may stop bladder bleeding without blood thinners
- New heart device aims to cut stroke risk without lifelong blood thinners